| Envafolimab | |
| Generic Name | Envafolimab |
| Company Name | KN035 |
| Drug Type | Antibody |
| Drug Class | Immune therapy |
| Dose | 300 mg per flat dose |
| Route | Subcutaneous |
| Schedule of Administration | In the dose exploration, patients received envafolimab as a single fixed dose of 300 mg on day 1 in each 28‐day cycle. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.